Clinical Trials Logo

Peripheral Edema clinical trials

View clinical trials related to Peripheral Edema.

Filter by:
  • None
  • Page 1

NCT ID: NCT04680533 Active, not recruiting - Peripheral Edema Clinical Trials

Wireless TENS for Peripheral Edema (Lower Limb Swelling)

Start date: June 28, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is single center, subject will receive a wireless TENS device. All subjects will be allowed to keep the commercially-available device for use after the study. The primary goal is to test the feasibility of the study design and secondary is to test the preliminary efficacy of the TENS.

NCT ID: NCT00305331 Terminated - Parkinson's Disease Clinical Trials

Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The dopamine agonists, pramipexole (Mirapex) and ropinirole (Requip), are drugs that are used to treat symptoms of Parkinson's disease. However, these drugs can induce bothersome leg swelling or edema in about 20 percent of patients. The cause of this edema is unknown but may be secondary to stimulation of peripheral dopamine receptors in the kidney or blood vessels. We hypothesise that a peripherally acting dopamine receptor antagonist, will reduce edema in PD patients. This study will assess the effect of the peripheral acting dopamine D2 receptor antagonist, domperidone as a potential treatment for dopamine agonist-induced leg swelling.

NCT ID: NCT00143793 Completed - Dyspnea Clinical Trials

NT-proBNP and New Biomarkers in Patients With Dyspnea and/or Peripheral Edema

MANPRO
Start date: June 2005
Phase:
Study type: Observational

The objectives of this study are to: - Evaluate the sensitivity and specificity of NT-proBNP (N-terminal prohormone brain natriuretic peptide) and new biomarker measurements for the diagnosis of heart failure in patients with acute dyspnea and/or edema. - Determine the exact biomarker cut-off point(s) for the differentiation of healthy persons, patients with heart failure and patients with dyspnea of other origin. - Evaluate treatment costs in patients with dyspnea under special consideration of NT-proBNP measurement.